{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:15:09Z","timestamp":1790162109709,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T00:00:00Z","timestamp":1264550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s00259-009-1356-x","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T16:28:18Z","timestamp":1264523298000},"page":"851-861","source":"Crossref","is-referenced-by-count":25,"title":["In vitro experimental 211At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin"],"prefix":"10.1007","volume":"37","author":[{"given":"Thorsten","family":"Petrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekiye","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Krull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Fr\u00f6mke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geerd J.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram H.","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,1,27]]},"reference":[{"key":"1356_CR1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","volume":"19","author":"ML Linenberger","year":"2005","unstructured":"Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005;19:176\u201382.","journal-title":"Leukemia"},{"key":"1356_CR2","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood.V85.8.2005.bloodjournal8582005","volume":"85","author":"SD Freeman","year":"1995","unstructured":"Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995;85:2005\u201312.","journal-title":"Blood"},{"key":"1356_CR3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2005.05872.x","volume":"132","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM, Giles FJ, Estey E, O\u2019Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 2006;132:398\u2013409.","journal-title":"Br J Haematol"},{"key":"1356_CR4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1182\/blood-2004-04-1550","volume":"104","author":"F Lo-Coco","year":"2004","unstructured":"Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004;104:1995\u20139.","journal-title":"Blood"},{"key":"1356_CR5","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood-2001-12-0174","volume":"99","author":"EH Estey","year":"2002","unstructured":"Estey EH, Giles FJ, Beran M, O\u2019Brien S, Pierce SA, Faderl SH, et al. Experience with gemtuzumab ozogamycin (\u201cmylotarg\u201d) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002;99:4222\u20134.","journal-title":"Blood"},{"key":"1356_CR6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/bc0100206","volume":"13","author":"PR Hamann","year":"2002","unstructured":"Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 2002;13:40\u20136.","journal-title":"Bioconjug Chem"},{"key":"1356_CR7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/1097-0142(19940201)73:3+<1049::AID-CNCR2820731344>3.0.CO;2-1","volume":"73","author":"PC Caron","year":"1994","unstructured":"Caron PC, Schwartz MA, Co MS, Queen C, Finn RD, Graham MC, et al. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer 1994;73:1049\u201356.","journal-title":"Cancer"},{"key":"1356_CR8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1634\/stemcells.20-3-215","volume":"20","author":"A Countouriotis","year":"2002","unstructured":"Countouriotis A, Moore TB, Sakamoto KM. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 2002;20:215\u201329.","journal-title":"Stem Cells"},{"key":"1356_CR9","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","volume":"97","author":"VH Velden van Der","year":"2001","unstructured":"van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001;97:3197\u2013204.","journal-title":"Blood"},{"key":"1356_CR10","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.3240341","volume":"240","author":"N Zein","year":"1988","unstructured":"Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988;240:1198\u2013201.","journal-title":"Science"},{"key":"1356_CR11","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1073\/pnas.89.10.4608","volume":"89","author":"S Walker","year":"1992","unstructured":"Walker S, Landovitz R, Ding WD, Ellestad GA, Kahne D. Cleavage behavior of calicheamicin gamma 1 and calicheamicin T. Proc Natl Acad Sci U S A 1992;89:4608\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1356_CR12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.leu.2401851","volume":"14","author":"K Naito","year":"2000","unstructured":"Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 2000;14:1436\u201343.","journal-title":"Leukemia"},{"key":"1356_CR13","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2003-02-0396","volume":"102","author":"RB Walter","year":"2003","unstructured":"Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003;102:1466\u201373.","journal-title":"Blood"},{"key":"1356_CR14","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","volume":"109","author":"RB Walter","year":"2007","unstructured":"Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007;109:4168\u201370.","journal-title":"Blood"},{"key":"1356_CR15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.leu.2403205","volume":"18","author":"I Jedema","year":"2004","unstructured":"Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, Willemze R, et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 2004;18:316\u201325.","journal-title":"Leukemia"},{"key":"1356_CR16","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood-2003-11-3825","volume":"103","author":"RB Walter","year":"2004","unstructured":"Walter RB, Raden BW, Cronk MR, Bernstein ID, Appelbaum FR, Banker DE. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 2004;103:4276\u201384.","journal-title":"Blood"},{"key":"1356_CR17","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2002-07-2311","volume":"101","author":"D Amico","year":"2003","unstructured":"Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood 2003;101:4589\u201397.","journal-title":"Blood"},{"key":"1356_CR18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0952-7915(91)90096-J","volume":"3","author":"DA Scheinberg","year":"1991","unstructured":"Scheinberg DA. Current applications of monoclonal antibodies for the therapy of hematopoietic cancers. Curr Opin Immunol 1991;3:679\u201384.","journal-title":"Curr Opin Immunol"},{"key":"1356_CR19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.1991.9.3.478","volume":"9","author":"DA Scheinberg","year":"1991","unstructured":"Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991;9:478\u201390.","journal-title":"J Clin Oncol"},{"key":"1356_CR20","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1158\/0008-5472.CAN-06-3569","volume":"67","author":"C Friesen","year":"2007","unstructured":"Friesen C, Glatting G, Koop B, Schwarz K, Morgenstern A, Apostolidis C, et al. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res 2007;67:1950\u20138.","journal-title":"Cancer Res"},{"key":"1356_CR21","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00259-002-0784-7","volume":"29","author":"T Petrich","year":"2002","unstructured":"Petrich T, Helmeke HJ, Meyer GJ, Knapp WH, P\u00f6tter E. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium\/iodide symporter. Eur J Nucl Med Mol Imaging 2002;29:842\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1356_CR22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0883-2889(88)90176-1","volume":"39","author":"MR Zalutsky","year":"1988","unstructured":"Zalutsky MR, Narula AS. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Int J Rad Appl Instrum A 1988;39:227\u201332.","journal-title":"Int J Rad Appl Instrum A"},{"key":"1356_CR23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.nucmedbio.2004.08.005","volume":"31","author":"VS Talanov","year":"2004","unstructured":"Talanov VS, Yordanov AT, Garmestani K, Milenic DE, Arora HC, Plascjak PS, et al. Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins. Nucl Med Biol 2004;31:1061\u201371.","journal-title":"Nucl Med Biol"},{"key":"1356_CR24","first-page":"277s","volume":"10","author":"A Walte","year":"2007","unstructured":"Walte A, Sriyapureddy SS, Korkmaz Z, Krull D, Bolte O, Hofmann M, et al. Preparation and evaluation of 211At labelled antineoplastic antibodies. J Pharm Pharm Sci 2007;10:277s\u201385.","journal-title":"J Pharm Pharm Sci"},{"key":"1356_CR25","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/(SICI)1097-0215(19980504)76:3<354::AID-IJC12>3.0.CO;2-B","volume":"76","author":"MI N\u00fa\u00f1ez","year":"1998","unstructured":"N\u00fa\u00f1ez MI, Guerrero MR, L\u00f3pez E, del Moral MR, Valenzuela MT, Siles E, et al. DNA damage and prediction of radiation response in lymphocytes and epidermal skin human cells. Int J Cancer 1998;76:354\u201361.","journal-title":"Int J Cancer"},{"key":"1356_CR26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000077461","volume":"104","author":"G Iliakis","year":"2004","unstructured":"Iliakis G, Wang H, Perrault AR, Boecker W, Rosidi B, Windhofer F, et al. Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet Genome Res 2004;104:14\u201320.","journal-title":"Cytogenet Genome Res"},{"key":"1356_CR27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1667\/RR0746.1","volume":"168","author":"B Pinar","year":"2007","unstructured":"Pinar B, Lara PC, Lloret M, Bord\u00f3n E, N\u00fa\u00f1ez MI, Villalobos M, et al. Radiation-induced DNA damage as a predictor of long-term toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy. Radiat Res 2007;168:415\u201322.","journal-title":"Radiat Res"},{"key":"1356_CR28","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1073\/pnas.93.6.2239","volume":"93","author":"DL Vaux","year":"1996","unstructured":"Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci U S A 1996;93:2239\u201344.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1356_CR29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0968-0004(97)01085-2","volume":"22","author":"DW Nicholson","year":"1997","unstructured":"Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997;22:299\u2013306.","journal-title":"Trends Biochem Sci"},{"key":"1356_CR30","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","volume":"106","author":"MS Tallman","year":"2005","unstructured":"Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154\u201363.","journal-title":"Blood"},{"key":"1356_CR31","doi-asserted-by":"crossref","first-page":"3556s","DOI":"10.1158\/1078-0432.CCR-06-9001","volume":"12","author":"RA Larson","year":"2006","unstructured":"Larson RA, Stone RM, Mayer RJ, Schiffer CA. Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. Clin Cancer Res 2006;12:3556s\u201363.","journal-title":"Clin Cancer Res"},{"key":"1356_CR32","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","volume":"99","author":"P Rajvanshi","year":"2002","unstructured":"Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002;99:2310\u20134.","journal-title":"Blood"},{"key":"1356_CR33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","volume":"31","author":"JM McKoy","year":"2007","unstructured":"McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007;31:599\u2013604.","journal-title":"Leuk Res"},{"key":"1356_CR34","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","volume":"92","author":"FJ Giles","year":"2001","unstructured":"Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001;92:406\u201313.","journal-title":"Cancer"},{"key":"1356_CR35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.107.046938","volume":"49","author":"MR Zalutsky","year":"2008","unstructured":"Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008;49:30\u20138.","journal-title":"J Nucl Med"},{"key":"1356_CR36","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.nucmedbio.2007.03.007","volume":"34","author":"MR Zalutsky","year":"2007","unstructured":"Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol 2007;34:779\u201385.","journal-title":"Nucl Med Biol"},{"key":"1356_CR37","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","volume":"50","author":"H Andersson","year":"2009","unstructured":"Andersson H, Cederkrantz E, B\u00e4ck T, Divgi C, Elgqvist J, Himmelman J, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab\u2019)2\u2014a phase I study. J Nucl Med 2009;50:1153\u201360.","journal-title":"J Nucl Med"},{"key":"1356_CR38","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.apradiso.2009.08.003","volume":"67","author":"N Tisnek","year":"2009","unstructured":"Tisnek N, Kalanxhi E, Serkland CW, Iversen J, Belyakov OV, Dahle J. A (238)Pu irradiator for exposure of cultured cells with alpha-radiation: construction, calibration and dosimetry. Appl Radiat Isot 2009;67:1998\u20132002.","journal-title":"Appl Radiat Isot"},{"key":"1356_CR39","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1667\/RR1536.1","volume":"171","author":"N Chouin","year":"2009","unstructured":"Chouin N, Bernardeau K, Bardi\u00e8s M, Faivre-Chauvet A, Bourgeois M, Apostolidis C, et al. Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. II. Application of the microdosimetric model to experimental results. Radiat Res 2009;171:664\u201373.","journal-title":"Radiat Res"},{"key":"1356_CR40","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s002590050306","volume":"25","author":"MR McDevitt","year":"1998","unstructured":"McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25:1341\u201351.","journal-title":"Eur J Nucl Med"},{"key":"1356_CR41","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2307\/3578139","volume":"128","author":"MR Raju","year":"1991","unstructured":"Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus. Radiat Res 1991;128:204\u20139.","journal-title":"Radiat Res"},{"key":"1356_CR42","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1158\/0008-5472.CAN-08-4363","volume":"69","author":"H Nakamae","year":"2009","unstructured":"Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, et al. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res 2009;69:2408\u201315.","journal-title":"Cancer Res"},{"key":"1356_CR43","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.2967\/jnumed.107.049833","volume":"49","author":"S Lindegren","year":"2008","unstructured":"Lindegren S, Frost S, B\u00e4ck T, Haglund E, Elgqvist J, Jensen H. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate. J Nucl Med 2008;49:1537\u201345.","journal-title":"J Nucl Med"},{"key":"1356_CR44","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/1078-0432.CCR-07-1250","volume":"14","author":"MK Robinson","year":"2008","unstructured":"Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, et al. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2\/neu diabodies. Clin Cancer Res 2008;14:875\u201382.","journal-title":"Clin Cancer Res"},{"key":"1356_CR45","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ijrobp.2006.07.003","volume":"66","author":"J Elgqvist","year":"2006","unstructured":"Elgqvist J, Andersson H, Bernhardt P, B\u00e4ck T, Claesson I, Hultborn R, et al. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab\u2019)2. Int J Radiat Oncol Biol Phys 2006;66:1228\u201337.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1356_CR46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1021\/bc7002428","volume":"19","author":"DS Wilbur","year":"2008","unstructured":"Wilbur DS, Hamlin DK, Chyan MK, Brechbiel MW. Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At. Bioconjug Chem 2008;19:158\u201370.","journal-title":"Bioconjug Chem"},{"key":"1356_CR47","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ijrobp.2007.06.023","volume":"69","author":"S Palm","year":"2007","unstructured":"Palm S, B\u00e4ck T, Claesson I, Danielsson A, Elgqvist J, Frost S, et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys 2007;69:572\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-009-1356-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-009-1356-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-009-1356-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T04:51:04Z","timestamp":1711169464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-009-1356-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,27]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1007\/s00259-009-1356-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,27]]}}}